Burning Rock Biotech Limited Announces First Quarter 2026 Financial Results

Burning Rock Biotech Limited reported its first quarter 2026 financial results, showing a decrease in revenues to RMB107.9 million (US$15.6 million) from RMB133.1 million in the same period of 2025. This decline was observed across all revenue streams: central laboratory business decreased by 15.3%, in-hospital business by 8.5% (excluding a one-off issue, it would have increased by 2%), and pharma R&D services by 38.6%. Consequently, the gross profit decreased by 19.9% to RMB78.0 million, with a slight reduction in gross margin to 72.3%. Operating expenses also decreased by 14.0% to RMB96.9 million, driven by cost control measures. The company reported a net loss of RMB17.5 million for the quarter, compared to RMB13.5 million in the prior year. Cash, cash equivalents, and restricted cash stood at RMB448.7 million as of March 31, 2026. The company also highlighted recent business updates, including the presentation of study results at the 2026 AACR and Journal for ImmunoTherapy of Cancer.